Clinical Trials
70 trialsPSMA SRT
Jonsson Comprehensive Cancer Center
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
First Affiliated Hospital of Fujian Medical University
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Jonsson Comprehensive Cancer Center
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
Jonsson Comprehensive Cancer Center
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
University of Washington
PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
UNC Lineberger Comprehensive Cancer Center
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
First Affiliated Hospital of Fujian Medical University
68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients
Peking Union Medical College Hospital
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
68Ga-PSMA PET/CT for Ra223 Assessment
Chang Gung Memorial Hospital
Re-treatment 225Ac-J591 for mCRPC
Weill Medical College of Cornell University
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
HEATWAVE
Jonsson Comprehensive Cancer Center
[68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer
British Columbia Cancer Agency
PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer
Mayo Clinic
GaPSMA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC
University of Iowa
High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer
Universitaire Ziekenhuizen KU Leuven
PET/MRI to Stage Prostate Cancer Patients
IRCCS San Raffaele
Phase I Trial of 225Ac-J591 in Patients With mCRPC
Weill Medical College of Cornell University
Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients
University Hospitals Cleveland Medical Center
Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer.
The First Affiliated Hospital of Anhui Medical University
PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
UNC Lineberger Comprehensive Cancer Center
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
M.D. Anderson Cancer Center
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Stanford University
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Stanford University
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Stanford University
Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions
Case Comprehensive Cancer Center
68Ga-PSMA PET/CT in Prostate Cancer
Sir Mortimer B. Davis - Jewish General Hospital
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
University of Michigan
68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer
First Affiliated Hospital of Fujian Medical University
Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer
University of Texas Southwestern Medical Center
68 Ga-PSMA for High Risk Prostate Cancer
The Methodist Hospital Research Institute
PET/MRI in Patients With Suspected Prostate Cancer
Medical University of Vienna
68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
University of Texas Southwestern Medical Center
Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer
University of Michigan
68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery
Jonsson Comprehensive Cancer Center
PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study
IRCCS San Raffaele
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
University of California, San Francisco
The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer
University of Texas Southwestern Medical Center
68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
Jonsson Comprehensive Cancer Center
Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
Jonsson Comprehensive Cancer Center
Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer
OHSU Knight Cancer Institute
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Stanford University
Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer
University of Michigan Rogel Cancer Center